Core Insights - Avoro Capital Advisors LLC acquired a new stake in Tango Therapeutics, purchasing 545,000 shares valued at approximately $4.58 million, representing about 0.40% ownership of the company [2] - Several institutional investors have increased their stakes in Tango Therapeutics, with Dynamic Technology Lab Private Ltd increasing its stake by 139.7% and Ameritas Investment Partners Inc. raising its stake by 78.8% [3] - Tango Therapeutics has a market capitalization of $2.47 billion, with a 1-year price range of $1.03 to $17.63 and a current trading price of $17.30 [4] Financial Performance - Tango Therapeutics reported an EPS of -$0.29, exceeding the consensus estimate of -$0.31 by $0.02, with a negative net margin of 151.15% and a negative return on equity of 50.30% [5] - Analysts forecast an EPS of -$1.19 for the current fiscal year [5] Analyst Ratings - HC Wainwright raised its price target for Tango Therapeutics from $13.00 to $27.00, while Stifel Nicolaus increased its target from $15.00 to $24.00, both giving a "buy" rating [6] - The average rating for Tango Therapeutics is "Moderate Buy" with a consensus target price of $19.50 [6] Insider Transactions - CFO Daniella Beckman sold 10,317 shares at an average price of $12.26, resulting in a 5.30% decrease in her position [7] - Director Barbara Weber sold 30,519 shares at the same average price, representing a 1.84% decrease in her holdings [7] Company Overview - Tango Therapeutics is a clinical-stage biotechnology company focused on developing precision medicines that target genetic vulnerabilities in cancer cells [8] - The company's lead pipeline includes early-stage programs aimed at selectively disabling DNA repair proteins in tumor cells [9]